SCHEMBL413416

SCHEMBL413416

O=C(O)CC(C(=O)OCCO)(N1C(=O)CCC1=O)N1C(=O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2524574 0.82
SCHEMBL30709586 0.80 ACHE (0.32)
Ethylene Glycol SCHEMBL10584826 0.78 ALDH1A1 (0.31)
Ethylene Glycol SCHEMBL413417 0.78 ALDH1A1 (0.31)
SCHEMBL3497998 0.78
SCHEMBL2335942 0.76
SCHEMBL3748421 0.76
Ethylene SCHEMBL4367126 0.76
SCHEMBL3719747 0.76 ALDH1A1 (0.34)
SCHEMBL5613498 0.76 POLB (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138575-B1 Conjugates comprising a biodegradable polymer and uses therefor MERSANA THERAPEUTICS INC (US) 2013-06-19 EP claimed
US-20110044967-A1 Conjugates Comprising a Biodegradable Polymer and Uses Therefor THE GENERAL HOSPITAL CORPORATION 2011-02-24 US claimed
EP-2138575-A1 Conjugates comprising a biodegradable polymer and uses therefor The General Hospital Corporation (US) 2009-12-30 EP claimed
EP-1585817-B1 CONJUGATES COMPRISING A BIODEGRADABLE POLYMER AND USES THEREFOR GEN HOSPITAL CORP (US) 2009-09-02 EP claimed
US-20050169968-A1 Conjugates comprising a biodegradable polymer and uses therefor THE GENERAL HOSPITAL CORPORATION 2005-08-04 US claimed
US-20050059068-A1 Compositions and methods using dendrimer-treated microassays STRATAGENE CALIFORNIA 2005-03-17 US claimed
WO-1995021380-A1 ASSAY FOR SCREENING OF RECEPTOR ANTAGONISTS LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 1995-08-10 WO claimed
US-20160334404-A1 VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE DIAZYME LABORATORIES, INC. 2016-11-17 US disclosed
EP-3049813-A2 LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 Diadexus, Inc. (US) 2016-08-03 EP disclosed
US-9297800-B2 Biomaterial construct, its producing method, biomaterial support, target material purifying method, affinity chromatography container, separation chip, analyzing method and analyzing separator for target material, biomaterial complex, and its support, sensor chip, solid support with biomaterial fixed thereon MITSUBISHI CHEMICAL CORPORATION (JP) 2016-03-29 US disclosed
WO-2015048177-A2 LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 DIADEXUS, INC. (US) 2015-04-02 WO disclosed
US-20150086998-A1 VALUE-ASSIGNED SOLUTIONS OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 HAVING A LONG SHELF-LIFE DIAZYME LABORATORIES, INC. 2015-03-26 US disclosed
US-20150086999-A1 LONG SHELF-LIFE KITS AND METHODS FOR STANDARDIZING, VERIFYING, CALIBRATING OR RECALIBRATING DETECTION OF LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 DIAZYME LABORATORIES, INC. 2015-03-26 US disclosed
WO-2001049720-A2 CHEMICALLY MODIFIED HIV ENVELOPE GLYCOPROTEIN AVENTIS PASTEUR (FR) 2001-07-12 WO disclosed
EP-1100926-A1 TRIMER OF HIV $i(ENV) GENE EXPRESSION PRODUCT Aventis Pasteur (FR) 2001-05-23 EP disclosed
WO-2000008167-A1 TRIMER OF HIV ENV GENE EXPRESSION PRODUCT AVENTIS PASTEUR (FR) 2000-02-17 WO disclosed
US-5935932-A Bradykinin antagonists containing pentafluorophenylalanine UNIVERSITY TECHNOLOGY CORPORATION (US) 1999-08-10 US disclosed
US-5916585-A POLYMERIC SURFACTANTS ATTACHED ONTO THE SURFACES OF A SUPPORT MEMBER AND COVALENTLY CROSS-LINKED THEREON TO FORM A FIRST LAYER. HYDROPHILIC POLYMERS ARE THEN ATTACHED TO THE FIRST LAYER ON THE SUPPORT MEMBER TO FORM A SECOND LAYER THEREON. GORE ENTERPRISE HOLDINGS, INC. (US) 1999-06-29 US disclosed
US-5876976-A Method for reducing carryover contamination in an amplification procedure AMGEN INC. (US) 1999-03-02 US disclosed
WO-1995021380-A1 ASSAY FOR SCREENING OF RECEPTOR ANTAGONISTS LUDWIG INSTITUTE FOR CANCER RESEARCH (US) 1995-08-10 WO disclosed